Why we should be more careful using hydroxychloroquine in influenza season during COVID-19 pandemic? | Zendy

Hülya Gamze Çelik | Zendy; Şiran Keske | Zendy; Ülker Şener | Zendy; Müge Tekbaş | Zendy; Mahir Kapmaz | Zendy; Şükrü Taylan Şahin | Zendy; Aslı Özyildirim | Zendy; Saide Aytekin | Zendy; Vedat Aytekin | Zendy; Önder Ergönül | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Why we should be more careful using hydroxychloroquine in influenza season during COVID-19 pandemic?

Author(s) -

Hülya Gamze Çelik,

Şiran Keske,

Ülker Şener,

Müge Tekbaş,

Mahir Kapmaz,

Şükrü Taylan Şahin,

Aslı Özyildirim,

Saide Aytekin,

Vedat Aytekin,

Önder Ergönül

Publication year - 2020

Publication title -

international journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.278

H-Index - 89

eISSN - 1878-3511

pISSN - 1201-9712

DOI - 10.1016/j.ijid.2020.10.080

Subject(s) - hydroxychloroquine , medicine , qt interval , odds ratio , confidence interval , torsades de pointes , covid-19 , pandemic , coronavirus , oseltamivir , cardiology , disease , infectious disease (medical specialty)

The aim of this study was to describe the QTc prolongation and related adverse cardiac events during the administration of hydroxychloroquine (HCQ) and its combinations for the treatment of coronavirus disease 2019 (COVID-19). Hospitalized patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who received HCQ and had initial and follow-up electrocardiograms performed between March 10 and May 30, 2020 were included. Critical QTc prolongation was detected in 12% of the patients. On multivariate analysis, diabetes mellitus (odds ratio 5.8, 95% confidence interval 1.11-30.32, p = 0.037) and the use of oseltamivir (odds ratio 5.3, 95% confidence interval 1.02-28, p = 0.047) were found to be associated with critical QTc prolongation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research